Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurotrope, Inc.NTRP · Entity 144906 | Director | December 01, 2020 | December 03, 2020 |
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Director | June 05, 2026 | June 05, 2026 |
| Q/C TECHNOLOGIES, INC.QCLS · Entity 7735 | Director | April 13, 2026 | April 15, 2026 |
| RRE Ventures Acquisition Corp.RREV · Entity 5843 | Director | March 02, 2026 | May 05, 2026 |
| TAO Synergies Inc.TAOX · Entity 7482 | Director | May 18, 2026 | May 19, 2026 |
| WRAP TECHNOLOGIES, INC.WRAP · Entity 6770 | Director | October 01, 2026 | October 10, 2026 |
| XWELL, Inc.XWEL · Entity 1233 | Director | August 25, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 1,565 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 7,813 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 15,535 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-01 · Disposition to issuer · Disposed 72,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Petros Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,762,334 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 1,875,000 · Balance 3,762,334 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.
Q/C TECHNOLOGIES, INC.
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2036-04-13 | Direct | 50,000 |
Reported balance
After 2026-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.
RRE Ventures Acquisition Corp.
Report date March 02, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 40,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 40,000 · Balance 40,000 F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: These securities were previously reported on a Form 3 filed by the Reporting Person. |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 115,000 |
Reported balance
After 2026-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-25 · Grant · Acquired 75,000 · Balance 115,000 F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: These securities were previously reported on a Form 3 filed by the Reporting Person. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 250,000 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 250,000 · Balance 250,000 F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
F2: These securities were previously reported on a Form 3 filed by the Reporting Person.
F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation.
TAO Synergies Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18 | Direct | 55,000 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 55,000 · Balance 55,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.
WRAP TECHNOLOGIES, INC.
Report date October 01, 2026 · Filed October 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,002 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 21,154 · Balance 272,002 F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches.
XWELL, Inc.
Report date August 25, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 839,882 |
Reported balance
After 2026-08-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-25 · Grant · Acquired 500,000 · Balance 839,882 F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2023 Filed Mar 31, 2023 20:16 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001104659-23-040191 · tm2311075-2_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 per share · 20,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following March 29, 2023. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 21:15 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionRestricted Stock Units · Derivative | 2,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-006542 · tm234334-1_4seq1.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 21:15 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionCommon Stock | 2,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-006542 · tm234334-1_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · price: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 02:36 UTC Amendment | XWELL, Inc. XWEL · Entity 1233 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001235110-23-000001 · edgar.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-01-05 F1 · security: This grant is pursuant to the directors compensation plan. F2 · derivative.exercise_date: The option vests in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each calendar quarter, such that the options will be fully vested as of December 31, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 19:05 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0000950138-23-000002 · edgar.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-01-05 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · derivative.exercise_date: The option vests in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2023. Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 01:00 UTC | TAO Synergies Inc. SNPX · Entity 7482 | SaleCommon Stock, par value $0.0001 per share | 22,500 | $1.17 | $26,367.75 |
DisclosureSEC source: 0001104659-22-128766 · tm2233089-2_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,578 F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:50 UTC | XWELL, Inc. XWEL · Entity 1233 | PurchaseCommon Stock | 33,890 | $0.43 | $14,572.70 |
DisclosureSEC source: 0000950138-22-000238 · edgar.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,198 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4201 to $0.4299. The Reporting Person undertakes to provide XWELL, Inc., any security holder of XWELL, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 21:50 UTC | XWELL, Inc. XWEL · Entity 1233 | PurchaseCommon Stock | 16,110 | $0.41 | $6,524.55 |
DisclosureSEC source: 0000950138-22-000238 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,308 Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:03 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-119882 · tm2230820-7_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock, par value $0.0001 per share · 80,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| November 15, 2022 Filed Dec 2, 2022 00:48 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-123799 · tm2231816-2_4aseq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 per share · 75,000 shares Expires 2032-11-15 F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Bernstein to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 21:00 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantRestricted Stock Units · Derivative | 60,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-044711 · tm2212468d1_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,505 Underlying: Common Stock · 60,505 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date. F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:00 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001104659-22-043271 · tm2212026-1_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock, par value $0.0001 per share · 1,500 shares Expires 2032-04-05 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022. Read SEC document |
| April 05, 2022 Filed Jun 23, 2022 22:00 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | OtherStock Option (Right to Buy) · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-073970 · tm2219110-1_4aseq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares Expires not disclosed F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Bernstein, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 23:17 UTC | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 5,000 | $1.23 | $6,150.00 |
DisclosureSEC source: 0000950138-22-000095 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,198 F1 · kind: The reporting person's purchase of XSPA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of shares of XSPA common stock on January 21, 2022. 3,000 shares were matched with sales of 3,000 shares at $1.52 per share and 2,000 shares were matched with sales of 2,000 shares at $1.47 per share on that date. The reporting person has agreed to pay to XSPA, upon settlement of the sale, $1,350, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs. F2 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:10 UTC | XWELL, Inc. XSPA · Entity 1233 | SaleCommon Stock | 15,000 | $1.00 | $14,928.00 |
DisclosureSEC source: 0000950138-22-000080 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,198 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9902 to $1.00, inclusive. The reporting person undertakes to provide to XpresSpa Group, Inc. any security holder of XpresSpa Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| January 26, 2022 Filed Feb 1, 2022 01:05 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000950138-22-000028 · edgar.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2032-01-26 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F4 · derivative.exercise_date: The options vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2022. Read SEC document |
| January 26, 2022 Filed Feb 1, 2022 01:05 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-22-000028 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,198 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · shares: Represents restricted stock units which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2022. F3 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 23:23 UTC | XWELL, Inc. XSPA · Entity 1233 | SaleCommon Stock | 25,000 | $1.46 | $36,545.00 |
DisclosureSEC source: 0000950138-22-000025 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,698 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.44 to $1.52, inclusive. The reporting person undertakes to provide to XpresSpa Group, Inc. any security holder of XpresSpa Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| December 22, 2021 Filed Jan 7, 2022 21:43 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantRestricted Stock Units · Derivative | 22,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002303 · tm222320d1_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,642 Underlying: Common Stock · 22,642 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 21:44 UTC | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 5,000 | $1.65 | $8,250.00 |
DisclosureSEC source: 0000950138-21-000522 · edgar.xml · nonDerivative · entry 3 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,698 F2 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 21:44 UTC | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 30,000 | $1.72 | $51,474.00 |
DisclosureSEC source: 0000950138-21-000522 · edgar.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,698 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.74, inclusive. The reporting person undertakes to provide to XpresSpa Group, Inc., any security holder of XpresSpa Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:44 UTC | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 2,500 | $1.67 | $4,165.00 |
DisclosureSEC source: 0000950138-21-000522 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,698 F2 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| August 19, 2021 Filed Aug 19, 2021 23:40 UTC | XWELL, Inc. XSPA · Entity 1233 | SaleCommon Stock | 107,500 | $1.43 | $153,219.75 |
DisclosureSEC source: 0000950138-21-000418 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,198 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.37 to $1.47, inclusive. The reporting person undertakes to provide to XpresSpa Group, Inc. any security holder of XpresSpa Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: The total also includes 500,000 restricted stock units, which were granted on July 29, 2021 and were previously reported and which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. Read SEC document |
| August 19, 2021 Filed Aug 21, 2021 00:24 UTC Amendment | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 107,500 | $1.43 | $153,219.75 |
DisclosureSEC source: 0000950138-21-000423 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,198 F1 · kind: The original Form 4, filed on August 19, 2021, is being amended by this Form 4/A solely to correct the transaction code of the purchase. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 21:13 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-21-000390 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,698 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · shares: Represents restricted stock units which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of June 30, 2022. F3 · balance_after: The Issuer effected a 1-for-3 reverse stock split on June 11, 2020. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 22:05 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092715 · tm2122331-3_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,078 F1 · balance_after: Includes 50,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:15 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007862 · doc1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (right to buy) · Derivative | 84,615 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001235110-21-000001 · edgar.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,615 Underlying: Common Stock · 84,615 shares Expires 2031-01-04 F4 · derivative.exercise_date: The option vests in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2021. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantCommon Stock | 55,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001235110-21-000001 · edgar.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,698 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F2 · shares: Represents restricted stock units which vest in equal quarterly installments over a one-year period, with one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2021. F3 · balance_after: The Issuer effected a 1-for-3 reverse stock split on June 11, 2020. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 72,500 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 9 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 8 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 7 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 6 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $8.91 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 5 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $19.10 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 4 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 15,535 | Not disclosed Strike: $10.56 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 3 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,535 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 7,813 | Not disclosed Strike: $16.32 | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,813 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-132152 · tm2037705d5_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 17:08 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 72,500 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-20-130078 · tm2037145d5_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). F2 · derivative.expiration_date: In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:57 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001104659-20-049351 · tm2016454d2_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-04-20 F1 · security: These securities were issued as part of the Issuer's equity grant to directors. F1 · price: These securities were issued as part of the Issuer's equity grant to directors. F2 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, with one-fourth vesting on the date of grant and one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2020. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 18:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001104659-20-037865 · tm2013506d3_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-20 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| March 15, 2019 Filed Apr 15, 2019 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001144204-19-019706 · tv518868_form4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-15 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:11 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001144204-19-007152 · tv513324_form4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2029-02-11 F1 · security: These securities were issued as part of the Issuer's annual equity grant to directors. F1 · price: These securities were issued as part of the Issuer's annual equity grant to directors. F2 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, with one-fourth vesting on the date of grant and one-fourth vesting at the end of each fiscal quarter, such that the options will be fully vested as of December 31, 2019. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:05 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002692 · tv511551_form4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-22 F1 · security: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| May 23, 2018 Filed May 23, 2018 21:48 UTC | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 10,000 | $0.35 | $3,500.00 |
DisclosureSEC source: 0001144204-18-030588 · tv494938_4.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,346 Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:48 UTC | XWELL, Inc. XSPA · Entity 1233 | PurchaseCommon Stock | 9,601 | $0.44 | $4,176.44 |
DisclosureSEC source: 0001144204-18-030588 · tv494938_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,346 Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:06 UTC | XWELL, Inc. XSPA · Entity 1233 | GrantClass A Warrant · Derivative | 250,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001144204-18-029211 · tv494342_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-05-15 F1 · price: The Class A Warrants were issued as consideration for the Reporting Person's execution of a consent and waiver in connection with the Issuer's private placement of 5% Secured Convertible Notes due 2019, Class A Warrants and Class B Warrants. F2 · ownership.nature: These securities are held by Rockmore Investment Master Fund Ltd., an investment entity controlled by Bruce T. Bernstein. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:04 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001144204-18-014969 · tv488499_form4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-13 F1 · shares: Represents the annual option grant to each of the Issuer's non-employee directors on the fifth business day after the Issuer's filing of its Annual Report on Form 10-K pursuant to the Issuer's Nonemployee Director Compensation Policy. Read SEC document |
| August 15, 2017 Filed Aug 21, 2017 20:06 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 1,500 | $1.13 | $1,695.00 |
DisclosureSEC source: 0001144204-17-044392 · v473744_form4.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,745 Read SEC document |
| August 15, 2017 Filed Aug 21, 2017 20:06 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 5,000 | $1.14 | $5,700.00 |
DisclosureSEC source: 0001144204-17-044392 · v473744_form4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,245 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.